[go: up one dir, main page]

PE20081693A1 - Derivados de cinolin-3-carboxamida como inhibidores de csf-1r - Google Patents

Derivados de cinolin-3-carboxamida como inhibidores de csf-1r

Info

Publication number
PE20081693A1
PE20081693A1 PE2008000185A PE2008000185A PE20081693A1 PE 20081693 A1 PE20081693 A1 PE 20081693A1 PE 2008000185 A PE2008000185 A PE 2008000185A PE 2008000185 A PE2008000185 A PE 2008000185A PE 20081693 A1 PE20081693 A1 PE 20081693A1
Authority
PE
Peru
Prior art keywords
csf
inhibitors
halo
amino
cinoline
Prior art date
Application number
PE2008000185A
Other languages
English (en)
Inventor
Leslie Dakin
Claude Afona Ogoe
David Scott
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39310013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081693A1 publication Critical patent/PE20081693A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO H, HALO, NITRO, CIANO, HIDROXI, ENTRE OTROS; R3 ES H, HALO; m ES 0-1; R4 ES HALO, NITRO, CIANO, TRIFLUOROMETOXI, AMINO, CARBOXI,ETOXI, ENTRE OTROS; n ES 0-5. SON COMPUESTOS PREFERIDOS: 7-ETOXI-4-[(2-FLUORO-4-METIL-FENIL)AMINO]-6-(4-METILPIPERAZIN-1-IL)CINOLIN-3-CARBOXAMIDA; 4-[(2,4-DIFLUOROFENIL)AMINO]-7-METOXI-6-(4-METILPIPERAZIN-1-IL)CINOLIN-3-CARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CSF-1R (FACTOR ESTIMULANTE DE COLONIAS 1) UTILES EN EL TRATAMIENTO DE CANCER
PE2008000185A 2007-01-25 2008-01-24 Derivados de cinolin-3-carboxamida como inhibidores de csf-1r PE20081693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88658507P 2007-01-25 2007-01-25
US95157607P 2007-07-24 2007-07-24

Publications (1)

Publication Number Publication Date
PE20081693A1 true PE20081693A1 (es) 2009-01-18

Family

ID=39310013

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000185A PE20081693A1 (es) 2007-01-25 2008-01-24 Derivados de cinolin-3-carboxamida como inhibidores de csf-1r

Country Status (18)

Country Link
US (2) US7723337B2 (es)
EP (1) EP2118072A1 (es)
JP (1) JP2010500988A (es)
KR (1) KR20090111337A (es)
AR (1) AR065042A1 (es)
AU (1) AU2008208751A1 (es)
BR (1) BRPI0808005A2 (es)
CA (1) CA2675621A1 (es)
CL (1) CL2008000191A1 (es)
CO (1) CO6190614A2 (es)
EC (1) ECSP099539A (es)
IL (1) IL199911A0 (es)
MX (1) MX2009007889A (es)
PE (1) PE20081693A1 (es)
RU (1) RU2009131834A (es)
TW (1) TW200843775A (es)
UY (1) UY30880A1 (es)
WO (1) WO2008090353A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102089286A (zh) * 2008-05-07 2011-06-08 阿斯利康(瑞典)有限公司 化合物
RU2637936C2 (ru) 2011-05-23 2017-12-08 Элан Фармасьютикалз, Инк. Ингибиторы активности киназы lrrk2
WO2013148603A1 (en) * 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
JP2019512512A (ja) * 2016-03-21 2019-05-16 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ シンノリン−４−アミン化合物およびその癌治療への使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH04211661A (ja) * 1990-03-28 1992-08-03 Otsuka Pharmaceut Co Ltd キノリン誘導体及び該誘導体を含有する抗潰瘍剤
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
WO2007119046A1 (en) 2006-04-14 2007-10-25 Astrazeneca Ab 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
TW200843775A (en) 2008-11-16
AR065042A1 (es) 2009-05-13
UY30880A1 (es) 2008-09-02
US7723337B2 (en) 2010-05-25
CO6190614A2 (es) 2010-08-19
ECSP099539A (es) 2009-08-28
KR20090111337A (ko) 2009-10-26
AU2008208751A1 (en) 2008-07-31
RU2009131834A (ru) 2011-02-27
BRPI0808005A2 (pt) 2013-07-30
EP2118072A1 (en) 2009-11-18
US20110098283A1 (en) 2011-04-28
MX2009007889A (es) 2009-07-31
US20090012084A1 (en) 2009-01-08
CA2675621A1 (en) 2008-07-31
CL2008000191A1 (es) 2008-08-22
JP2010500988A (ja) 2010-01-14
WO2008090353A1 (en) 2008-07-31
IL199911A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20081693A1 (es) Derivados de cinolin-3-carboxamida como inhibidores de csf-1r
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20130647A1 (es) Indoles
PA8632701A1 (es) Compuestos terapeuticos
PE20090772A1 (es) Derivados de bencimidazol
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
ATE433981T1 (de) Heterocyclische verbindungen
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
MX2010005033A (es) Aminas heterociclicas fungicidas.
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20110546A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos
PE20091066A1 (es) 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
ATE452896T1 (de) C3-cyanoepothilonderivate

Legal Events

Date Code Title Description
FC Refusal